Madhya Pradesh Online Journal

Metastatic Renal Cell Carcinoma Pipeline Landscape: 40+ Key Players | DelveInsight

 Breaking News
  • No posts were found

Metastatic Renal Cell Carcinoma Pipeline Landscape: 40+ Key Players | DelveInsight

November 15
01:17 2022
Metastatic Renal Cell Carcinoma Pipeline Landscape: 40+ Key Players | DelveInsight

DelveInsight’s, “Metastatic Renal Cell Carcinoma Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Metastatic Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Metastatic Renal Cell Carcinoma Pipeline Insight Report

  • DelveInsight’s metastatic renal cell carcinoma pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline therapies.
  • Some of the key pharmaceutical players working to develop potential metastatic renal cell carcinoma drug candidates to improve the metastatic renal cell carcinoma treatment landscape include AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4 Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., Betta Pharmaceuticals, Exelixis, Hutchison Medipharma Limited, Sumitomo Pharma, NGM Biopharmaceuticals, Ocellaris Pharma, Oncorena AB, and others.
  • Key metastatic renal cell carcinoma pipeline therapies in various stages of development include Olaparib, Atezolizumab, TP-1454, ALLO 316, SO-C101, VB10.NEO, PF-07209960, INCB001158, IPI-549, DSP-7888, Belzutifan, CD70 CAR-T, Sitravatinib, Pexastimogene Devacirepvec, Gevokizumab, AK104, CCT301-38, Pamiparib, ONC-392, Batiraxcept, AZD6738, NBTXR3, NKT2152, Bempegaldesleukin, Abemaciclib, Abexinostat, CM082, Savolitinib, Epacadostat, MEDI4736, XL092, Fruquintinib,  DSP-7888, NGM 707, OC-001, Orellanine, and others.
  • In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Recent Breakthroughs of the Metastatic Renal Cell Carcinoma Treatment Landscape

  • In September 2022, The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized Phase III trial of neoadjuvant immunotherapy in patients with kidney cancer. At a planned interim analysis, the trial showed no difference in recurrence-free survival (RFS) between arms in a population of patients that included both clear cell and non-clear cell subtypes, and was stopped early.
  • In March 2022, Allogene Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) had granted Fast Track designation (FTD) to ALLO-316, the Company’s first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). The FDA granted FTD based on the potential of ALLO-316 to address the unmet need for patients with difficult-to-treat renal cell carcinomas (RCC) who have failed standard RCC therapies.
  • In February 2022, Eisai and Merck & Co., Inc., announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) had approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., for radically unresectable or metastatic renal cell carcinoma (RCC).
  • In July 2021, City of Hope and Osel Inc. announced that the City of Hope had granted an exclusive worldwide license to Osel for intellectual property on the novel use of an LBP CBM588 to enhance the efficacy of checkpoint inhibitors to treat cancer, including metastatic renal cell carcinoma.

 

Request a sample and discover the recent advances in Metastatic Renal Cell Carcinoma Medication @ Metastatic Renal Cell Carcinoma Treatment Landscape

 

Metastatic Renal Cell Carcinoma Overview

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 85% of neoplasms arising from the kidney. Renal cell carcinoma may remain clinically occult for most of its course. Only 10% of patients present with the classic triad of flank pain, hematuria, and flank mass. Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases. The clinical management of patients with metastatic RCC is complicated by the lack of significant efficacy from available therapies. Common sites of metastases include the lung, liver, bone, brain, and adrenal gland, with case reports detailing the capacity of RCC to appear almost anywhere in the body. More than one organ system is often involved in the metastatic process. Metastases may be found at diagnosis or at some interval after nephrectomy. Approximately 20% to 50% of patients will eventually develop metastatic disease after nephrectomy. A shorter interval between nephrectomy and the development of metastases is associated with a poorer prognosis. Patients with metastatic RCC face a dismal prognosis, with a median survival time of only 6 to 12 months and a 2-year survival rate of 10% to 20%.

 

Metastatic Renal Cell Carcinoma Emerging Drugs

Olaparib: AstraZeneca

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014. Currently, it is in Phase II stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma. 

Atezolizumab: Genentech

Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. Currently, it is in Phase III stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma. 

TP-1454: Sumitomo Dainippon Pharma

TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator,that is currently being evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors (NCT04328740). TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.

 

Metastatic Renal Cell Carcinoma Pipeline Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Metastatic Renal Cell Carcinoma.   
  • In the coming years, the Metastatic Renal Cell Carcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Metastatic Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Metastatic Renal Cell Carcinoma treatment market. Several potential therapies for Metastatic Renal Cell Carcinoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Metastatic Renal Cell Carcinoma market size in the coming years. 
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Metastatic Renal Cell Carcinoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Find out more about the disease and metastatic renal cell carcinoma guidelines @ Metastatic Renal Cell Carcinoma Treatment

 

Metastatic Renal Cell Carcinoma Pipeline Therapeutic Analysis

There are approx. 40+ key companies which are developing the therapies for Metastatic Renal Cell Carcinoma. The companies which have their Metastatic Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Genentech.

 

DelveInsight’s Metastatic Renal Cell Carcinoma Pipeline report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Learn more about the emerging Metastatic Renal Cell Carcinoma pipeline therapies @ Metastatic Renal Cell Carcinoma Clinical Trials

 

Scope of the Metastatic Renal Cell Carcinoma Pipeline Insight Report

  • Coverage- Global
  • Metastatic Renal Cell Carcinoma Pipeline Assessment by Product Type
  • Metastatic Renal Cell Carcinoma Pipeline Assessment by Stage and Product Type
  • Metastatic Renal Cell Carcinoma Pipeline Assessment by Route of Administration
  • Metastatic Renal Cell Carcinoma Pipeline Assessment by Stage and Route of Administration
  • Metastatic Renal Cell Carcinoma Pipeline Assessment by Molecule Type
  • Metastatic Renal Cell Carcinoma Pipeline Assessment by Stage and Molecule Type
  • Metastatic Renal Cell Carcinoma Companies- AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4 Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., Betta Pharmaceuticals, Exelixis, Hutchison Medipharma Limited, Sumitomo Pharma, NGM Biopharmaceuticals, Ocellaris Pharma, Oncorena AB, and others
  • Metastatic Renal Cell Carcinoma Pipeline Therapies- Olaparib, Atezolizumab, TP-1454, ALLO 316, SO-C101, VB10.NEO, PF-07209960, INCB001158, IPI-549, DSP-7888, Belzutifan, CD70 CAR-T, Sitravatinib, Pexastimogene Devacirepvec, Gevokizumab, AK104, CCT301-38, Pamiparib, ONC-392, Batiraxcept, AZD6738, NBTXR3, NKT2152, Bempegaldesleukin, Abemaciclib, Abexinostat, CM082, Savolitinib, Epacadostat, MEDI4736, XL092, Fruquintinib,  DSP-7888, NGM 707, OC-001, Orellanine, and others

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Renal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Atezolizumab: Genentech
  9. Mid Stage Products (Phase II)
  10. Olaparib: AstraZeneca
  11. Early Stage Products (Phase I)
  12. TP-1454: Sumitomo Dainippon Pharma
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Metastatic Renal Cell Carcinoma Key Companies
  17. Metastatic Renal Cell Carcinoma Key Products
  18. Metastatic Renal Cell Carcinoma- Unmet Needs
  19. Metastatic Renal Cell Carcinoma- Market Drivers and Barriers
  20. Metastatic Renal Cell Carcinoma- Future Perspectives and Conclusion
  21. Metastatic Renal Cell Carcinoma Analyst Views
  22. Metastatic Renal Cell Carcinoma Key Companies
  23. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Metastatic Renal Cell Carcinoma drugs?
  • How many Metastatic Renal Cell Carcinoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Renal Cell Carcinoma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Renal Cell Carcinoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Metastatic Renal Cell Carcinoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Got Queries? Get in touch with our Business Development Executive @ Metastatic Renal Cell Carcinoma Market Drivers and Barriers

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories